Elaborated Fragments. For so long as Serono is continuing to use [...***...] in accordance with Section 4.5 to [...***...] for a particular [...***...] that is [...***...]the activity of a specific [...***...], SGX [...***...] from ***CONFIDENTIAL TREATMENT REQUESTED which the [...***...] was derived to develop [...***...], [...***...].
Appears in 2 contracts
Sources: Collaboration Agreement (SGX Pharmaceuticals, Inc.), Collaboration Agreement (SGX Pharmaceuticals, Inc.)